Study of Palbociclib in MLL-rearranged Acute Leukemias

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02310243
• Other study ID #: AMLSG 23-14
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2015
• Est. completion date: July 2019

Study information

• Verified date: April 2019
• Source: University of Ulm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label

• Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and glioblastoma, this regimen will be chosen for the first dose to be evaluated in the phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib for the phase IIa is defined.

• Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest. Based on the optimal two-stage design of Simon, 21 patients are treated in the first stage. If results are positive, 29 additional patients will be recruited into the second stage of the study. An efficacy of the investigational therapy will be rejected in the first stage of 21 treated patients if two or less patients achieve complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during this first stage, the trial is intended to be continued in the second stage with a total sample size of 50 patients.

Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient out): July 2018 The treatment duration of an individual patient is estimated to be 2-6 months, but may be unlimited in patients with sustained response ("case-by-case decision").

Observation time per patient after entry into the study (incl. treatment) is at least 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according to the 2008 WHO Classification

• Patients with MLL-rearranged leukemia who are refractory to standard induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

• Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

• Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for intensive first-line therapy

• Genetic/histologic/immunohistologic assessment in one of the central laboratories

• Age = 18 years, no upper age limit

• WHO performance status of = 2

• No prior chemotherapy two weeks before study entry except hydroxyurea to control hyperleukocytosis

• Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).

• Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for three months after the last dose of therapy.

• Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.

• Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for three months after therapy is stopped, even if they have undergone successful vasectomy.

• Signed written informed consent

Exclusion Criteria:

• Prior treatment with palbociclib

• Performance status > 2 according to WHO criteria

• Organ insufficiency: creatinine > 1.5 x upper normal serum level; bilirubin, AST, or AP > 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder

• Uncontrolled infection

• Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.

• Severe neurologic or psychiatric disorder interfering with ability of giving informed consent

• Known or suspected active alcohol or drug abuse

• Known positivity for HIV, active HAV, HBV, or HCV infection

• Bleeding disorder unrelated to leukemia

• Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is allowed)

• QTc > 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes

• Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)

• No consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation

• No consent for biobanking

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Palbociclib
oral, once daily (125mg, 100mg or 75mg) for 21 days

Locations

Country	Name	City	State
Germany	Klinikum Augsburg	Augsburg
Germany	Helios Klinikum Bad Saarow	Bad Saarow
Germany	Charité Campus Benjamin Franklin	Berlin
Germany	Charité Campus Virchow-Klinikum	Berlin
Germany	Vivantes Klinikum Neukölln	Berlin
Germany	Universitätsklinikum Bonn	Bonn
Germany	Städtisches Klinikum Braunschweig gGmbH	Braunschweig
Germany	Universitätsklinikum Düsseldorf	Düsseldorf
Germany	Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH	Essen
Germany	Malteser Krankenhaus St. Franziskus-Hospital	Flensburg
Germany	Universitätsklinikum Freiburg	Freiburg
Germany	MVZ Osthessen	Fulda
Germany	Universitätsklinikum Giessen	Giessen
Germany	Universitätsklinikum Hamburg-Eppendorf	Hamburg
Germany	Medizinische Hochschule Hannover	Hannover
Germany	Universitätsklinikum Heidelberg	Heidelberg
Germany	Städtisches Klinikum Karlsruhe gGmbH	Karlsruhe
Germany	Universitätsklinikum Schleswig-Holstein Campus Kiel	Kiel
Germany	Caritas-Krankenhaus Lebach	Lebach
Germany	Uni-Klinikum der Otto-von-Guericke-Universität	Magdeburg
Germany	Universitätsmedizin der Johannes Gutenberg-Universität	Mainz
Germany	Pius Hospital Oldenburg	Oldenburg
Germany	Medizinische Universitätsklinik Tübingen	Tübingen
Germany	University Hospital of Ulm	Ulm

Sponsors (3)

Lead Sponsor	Collaborator
University of Ulm	National Center for Tumor Diseases, Heidelberg, Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events	Safety assessments	12 months
Primary	Maximum tolerated dose of palbociclib		12 months
Primary	overall response rate		12 months
Secondary	Relapse-free survival		three years
Secondary	Overall survival		three years
Secondary	Evaluation of target (CDK6) inhibition by palbociclib		three years
Secondary	Assessment of Quality of life		6 months